# Semaglutide Slows Aging in HIV Patients

> New study shows GLP-1 drug reduces biological aging markers in HIV patients.
- Title: Semaglutide Slows Aging in HIV Patients | Shortify
- Summary: New study shows GLP-1 drug reduces biological aging markers in HIV patients. Semaglutide slowed biological aging by 9% in HIV patients with lipohypertrophy…
- Keywords: semaglutide, hiv, lipohypertrophy, epigenetic clocks, dunedinpace, pcgrimage, telomeres, glp-1, uc san diego, stein institute, technology, startups
- Source: University of California — https://universityofcalifornia.edu/news/new-study-shows-popular-glp-1-weight-loss-drug-may-slow-biological-aging
- Published: 2026-06-12T01:18:24+00:00
- Read time: 1 min
- Topics: semaglutide, hiv, lipohypertrophy, epigenetic clocks, dunedinpace, pcgrimage, telomeres, glp-1, uc san diego, stein institute, technology, startups
## New Study Finds
Semaglutide slowed biological aging across multiple epigenetic clocks in HIV patients.
## Clinical Trial Details
108 adults with HIV-associated lipohypertrophy received weekly semaglutide or placebo injections.
## Epigenetic Clocks
Researchers tracked DNA methylation changes using DunedinPACE and PCGrimAge epigenetic clocks.
## Key Findings
Semaglutide slowed biological aging by 9% and reduced mortality risk markers in HIV patients.
## Mechanisms
GLP-1 drugs reduced inflammation and visceral fat to slow aging processes in HIV patients.
## Lead Researcher
Michael Corley, Ph.D., UC San Diego associate professor, led the study on aging in HIV.
## Broader Implications
Findings may benefit general population due to shared aging mechanisms in HIV and healthy individuals.
## Related Study
Pilot study reduced aging rate in 42% of HIV patients with fatty liver disease after 24 weeks.
## Future Research
Larger trials needed to confirm effects and determine optimal dosing for aging interventions.
## Key takeaway

Semaglutide slowed biological aging by 9% in HIV patients with lipohypertrophy, measured by epigenetic clocks.